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Abstract
Background: Human immunodeficiency virus (HIV) is responsible for millions of deaths every year. The current treatment
involves the use of multiple antiretroviral agents that may harm patients due to their toxic nature. RNA interference (RNAi) is
a potent candidate for the future treatment of HIV, uses short interfering RNA (siRNA/shRNA) for silencing HIV genes. In this
study, attempts have been made to create a database HIVsirDB of siRNAs responsible for silencing HIV genes.
Descriptions: HIVsirDB is a manually curated database of HIV inhibiting siRNAs that provides comprehensive information
about each siRNA or shRNA. Information was collected and compiled from literature and public resources. This database
contains around 750 siRNAs that includes 75 partially complementary siRNAs differing by one or more bases with the target
sites and over 100 escape mutant sequences. HIVsirDB structure contains sixteen fields including siRNA sequence, HIV strain,
targeted genome region, efficacy and conservation of target sequences. In order to facilitate user, many tools have been
integrated in this database that includes; i) siRNAmap for mapping siRNAs on target sequence, ii) HIVsirblast for BLAST
search against database, iii) siRNAalign for aligning siRNAs.
Conclusion: HIVsirDB is a freely accessible database of siRNAs which can silence or degrade HIV genes. It covers 26 types of
HIV strains and 28 cell types. This database will be very useful for developing models for predicting efficacy of HIV inhibiting
siRNAs. In summary this is a useful resource for researchers working in the field of siRNA based HIV therapy. HIVsirDB
database is accessible at http://crdd.osdd.net/raghava/hivsir/.
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Introduction
HIV/AIDS is a major global health threat as 33.3 million peoples
around the world were living with HIV by the end of December
2009 and this number is increasing with alarming rate [UNAIDS
reports: http://www.unaids.org/en/media/unaids/contentassets/
documents/factsheet/2010/20101123_FS_Global_em_en.pdf. In
2009 alone, 2.6 million people were newly infected and 1.8 million
AIDS related deaths occurred. AIDS was initially noticed in 1981
and its causative agent HIVwas discovered in 1983 [1,2,3]. HIV is a
positive strand RNA retrovirus which has very high genetic
variability due to its fast replication (109 to 1010 virions every day)
and high mutation rate of,361025 per nucleotide base per cycle of
replication [4]. These mutations resulted in the generation of many
different strains of HIV [5,6].
Currently, there is no drug that completely cures HIV infection
(http://www.lanl.gov/discover/curing_aids) and also no vaccine
to prevent from future infection [7]. There are few antiretroviral
drugs that can slow the disease progression by inhibiting the
function of proteins involved at different stages of the HIV life-
cycle. However, after span of time HIV become resistant to even
these drugs due to high rate of genetic mutation. Moreover, even
highly active antiretroviral therapy HAART (a combination of
three-four antiretroviral drugs) cannot totally eradicate the viruses
as some reside as latent reservoir in the host genome and remain in
dormant stage [8].
The continuing threat of HIV infection and non-availability of
complete cure necessitate the search for new approaches to curb
HIV infection. The recent discovery of RNA interference (RNAi)
mechanism in mammalian cells [9] raises the possibility to harness
this as a therapeutic tool against HIV [10,11]. Whenever, cell
encounters double stranded RNAs it triggers the RNAi response in
which dicer enzyme recognizes and cleaves dsRNAs into duplexes
of 19 to 21 nucleotides called siRNA. One strand of siRNA is loaded
into multi-protein RNA Induced Silencing Complex (RISC) and act
as guide sequence. siRNA-RISC complex recognize the target
mRNA or viral RNA having perfect Watson-Crick base pairing
and promote ribonuclease mediated degradation of the targeted
RNA [12].
The potential of RNAi to inhibit HIV infection was first
demonstrated in 2002 by several studies [10,11,13]. Subsequently,
a number of studies have been carried out using siRNAs and
shRNAs targeting HIV genome regions such as tat, rev, gag, pol,
nef, vif, env, vpr, and the long terminal repeat (LTR) in infected
cells and showed promising results to inhibit viral production
[14,15,16,17,18]. However, it has been shown that knockdown
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effect (efficacy) of siRNA varies according to its sequence and
target site on mRNA and hence results in limited number of highly
potent siRNAs. A large number of experimental studies have been
carried out in order to understand the features associated with
effective siRNAs and these features are implemented to develop
algorithms to predict potent siRNAs [19,20,21,22]. There are few
databases of siRNAs such as: (a) siRecords [23], (b) siRNAdb [24],
(c) HuSiDa [25] that focus on targeting genes of human and other
mammals.
In the last decade, numerous studies have reported the use of
siRNAs and shRNAs to inhibit the HIV. However, to best of
authors’ knowledge there is no database of siRNAs/shRNAs
targeting HIV. So, it’s difficult for the researchers to search and
analyze the data from the literature. Therefore, it becomes very
important to develop a comprehensive database in order to
facilitate research on potential RNAi based therapeutics against
HIV. Hence, a manually curetted database, ‘‘HIVsirDB’’, has
been developed with information of experimentally validated
published siRNAs and shRNAs targeting various HIV genome
regions.
Materials and Methods
Data source
The database collection is entirely based on data gathered from
published siRNA related studies. For the making of the collection of
siRNA or shRNA targeting HIV, queries were made on the PubMed
database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed/)
with keywords ‘‘((siRNA)OR shRNA) ANDHIV)’’. It retrieves almost
700 articles including 97 reviews as on 14th March, 2011. These
articles were examined and unrelated articles (siRNA targeting host
gene, reviews and some methodological articles where no siRNA
experiments were reported) were eliminated. Articles in non-English
languages were also excluded. The remaining articles were carefully
scrutinized. Furthermore, position of target in the HIV genome is
cross checked with NCBI accession number. If NCBI accession of
genome is not given, it was retrieved using information of HIV-strain,
position and sequence of target sites. A request was made to the
respective authors for efficacy in numerical values or extracted if it’s
given in graphical format. Thus, data of more than 750 siRNAs/
shRNAs targeting HIV were collected.
Data structure
The HIVsirDB contains the following sixteen fields for each
siRNAs entry as shown in the figure 1; (i) HIVsir ID, (ii) HIV
Strain, (iii) NCBI Accession, (iv) Target Gene, (v) Position of
siRNA target, (vi) Sense Sequence of siRNA, (vii) Length of
siRNA, (viii) Efficacy (%), (ix) GC Content (%), (x) Cell Line, (xi)
siRNA Source, (xii) Transfection Reagent, (xiii) Test Objective,
(xiv) Test Method, (xv) Test Time (Hours), (xvi) PubMed. Two
additional fields have been included in the main database to
accommodate information about the conservation of the target
sequences and escape studies.
Web interface and application
The HIVsirDB has been created using open source software
LAMP (Linux-Apache-Mysql-PHP) server technology. PHP, HTML
and CSS technologies have been used to build the web interface.
MySQL, an object-relational database management system
(RDBMS), works at the backend and provides commands to retrieve
and store siRNAs data into database. PHP a server side scripting
language provides interface and functions to fetch and displays data
from the database. The whole software system runs on IBM SAS
63800 machine under Red Hat Enterprise Linux 5 environment
using Apache httpd server. PHP and MySQL combination is quite
efficient and powerful for database management.
Figure 1. A schematic representation of architecture of database HIVsirDB.
doi:10.1371/journal.pone.0025917.g001
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Results
HIVsirDB database contains manually curated entries of
around 750 siRNA/shRNAs against HIV-1 as per literature
search till 14th March, 2011. These entries also include 75 partially
complementary siRNAs/shRNAs which were differing by one or
more bases with the target sites. Database have siRNA entries
targeting as many as 26 different HIV stains but majorly HIV-1
NL4-3 and LAI strains were used. Although database has siRNA
targeting every regions of HIV genome but predominant regions
were Pol, LTR and gag. 293T and Hela cell line were the
preferred cell lines used in the experiments. siRNA/shRNA used
were of different lengths ranging from 18 to 27 mer, however
majority were of 19 or 21 mer. Almost 36% entries of the database
constitute of highly efficacious (90–100%) siRNAs. The statistics of
the database is given in figure 2.
HivsirMut contains information of 107 escape mutants
sequences reported for 41 siRNAs available in the main database.
It includes details of siRNA and escape target sequence; efficacy of
escape mutant; type and number of escape mutation. One, two
and three substitutions were reported in 66, 16 and 10 escape
sequences respectively (total 88 sequences) and in 14 escape
sequences deletions of one or more nucleotide were reported. As
many as in 5 sequences, entire 19 bp target region was deleted. In
4 escape sequences both substitutions and deletions were reported.
Numbers of escape mutations at each positions of HIV sequence
targeted by siRNA are given in table S1. Maximum 12 escape
substitution mutations were observed at position 8 and 9 while
maximum deletion mutations were found at position 5.
HivsirMut also have information of 75 partially complementary
siRNAs entries which include 55 single mismatches, 8 double
mismatch, 9 triple mismatches and 4 multiple mismatch. In total,
there are 111 mismatch or mutation pairs reported. These
mismatches were present as different HIV strains were tested for
the same siRNA or mutated siRNAs were tested on the same HIV
strain. Number of mismatches between siRNA and the HIV target
sequence at different positions are given in table S1. Maximum of
15 mismatches were observed at position 12.
Utility Tools
For the better retrieval and analysis of the siRNA data from
database we have integrated various tools as search, advance
search and browsing. Besides, siRNA mapping and alignment
tools were also implemented to further enhance the scope of
database. Web tools integrated in HIVsirDB are as follow:
Keyword search and advance search
A simple text search tool is provided for searching all fields or on
selected fields of database and users are free to display all or
selected fields. The advance search provides users the best way to
search database making various combinations of fields using
logical operators ‘‘AND & OR’’ to make advance query for getting
more refined results. An export function (CSV) for search results is
also included to help the users in sorting the data.
Browse
This tool helps the user to retrieve siRNA information from
database by browsing five important fields viz. HIV Strain, Target
Genome Region, Cell Type, Efficacy, and GC Content. This
option makes the interface of database more user-friendly.
siRNA Analysis Tools
siRNAmap, HIVsirblast, siRNAalign are three important
siRNA analysis tools provided in HIVsirDB. It also has links for
the other siRNA resources. In siRNAmap interface user will
provide any genome region/gene sequence of HIV and output will
show mapping of siRNA/shRNA entries from our database on the
user provided sequence. Result shows how many siRNAs have
been reported earlier for that sequence along with efficacy and
respective positions. Clicking on any result entry, user will get
complete information available for that siRNA in the HIVsirDB.
Figure 2. Statistics of important fields included in HIVsirDB. (A) HIV strains. (B) HIV genome regions targeted. (C) Efficacy of siRNA/shRNA. (D)
Cell line used.
doi:10.1371/journal.pone.0025917.g002
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HIVsirblast tool search similar siRNAs in HIVsirDB along with
pairwise comparison with the user input siRNA sequence.
siRNAalign tool align the user provided siRNA sequence with the
1496 HIV reference sequences (available at http://www.hiv.lanl.
gov/content/sequence/HIV/mainpage.html) using QuickAlign.
Output of siRNAalign in the form of multiple sequence alignment
shows the siRNA target sequence conservation or variation among
different HIV strains and helps the user to choose the best siRNA.
External links of other Non-HIV siRNA database and general
siRNAs prediction programs etc. are also provided to help the users.
Output of the siRNA analysis tools is shown in figure 3.
Online submission
In order to add more siRNAs entries specific to HIV genome,
the HIVsirDB has online submission option for the users. The user
can add new siRNAs/shRNAs related information within specified
fields and subsequently entries will be added to the database after
proper validation.
Figure 3. Output of siRNA analysis tools. (A) siRNAmap to map siRNA on user provided HIV sequence. (B) HIVsirDBblast to provide similar siRNA
sequences in the database. (C) siRNAalign to find the siRNA sequence variation among different HIV strains.
doi:10.1371/journal.pone.0025917.g003
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Discussion
RNAi has shown great potential to investigate gene functions
and as a potential new class of drugs to suppress disease-causing
genes. The beauty of the system that makes it a powerful tool lies
in sequence specificity towards particular gene, its quick effect,
easiest and most cost effective. RNAi based potential therapeutics
would offer advantage over traditional drug molecules as 1) RNAi
can target any gene so eventually every protein, but traditional
drugs majorly target only certain classes of proteins e.g. G-protein-
coupled receptors and ion channels etc. 2) RNAi can block the
production of disease-causing proteins before they are made,
therefore have greater potential in disease control and interven-
tion. 3) Most importantly, the junction of two protein producing
genes as well as regulatory elements could be an important target
site, which is only possible by siRNA. 4) As the HIV genome
integrates into host genome and persists thus there is great
potential to inactivate only HIV genome by using siRNA based
approaches.
Unfortunately, HIV may escape the effect of siRNA by
mutations in the siRNA target sequences. These escape mutations
can decrease or altogether abolish the siRNA inhibition effect. We
have collected 107 such HIV escape mutant sequences targeted by
41 siRNAs. Substitution mutations are observed in majority of
sequences and clustered around the middle region of the target
sequence i.e. 8 to 11 positions. It seems that escape substitution
mutations are preferred in the middle region than flanking regions
of the target sequences. Simultaneously, deletion mutations were
scattered through all the positions in the target sequences.
The mutation generated at target site or nearby results either (A)
lack of 100% complementarities between target and siRNA
[26,27] or (B) target site forms a secondary structure and thus not
accessible for siRNAs that abolish the siRNA effect [28]. To
overcome escape mutants, design of siRNAs targeting highly
conserved genome regions that are essential for virus life cycle are
preferred. Another promising approach is co-expressing multiple
shRNAs that simultaneously target different regions of the viral
genome [29,30,31] or inhibition of HIV-1 replication with RNAi
against cellular co-factors [32].
We have checked the conservation of target sequences of each
siRNA among 1496 HIV reference sequences. Analysis showed
that for only 1% siRNA were conserved in over 90% target
sequences. It could be attributed to high variation among HIV
reference sequences. For 13% siRNA target sequences conserva-
tion was between 80–90% while 45% siRNA has less than 50%
target conservation.
In the database, most of the siRNA efficacy was observed in
293T and Hela cell lines. One potential problem could be the
interpretation of these results when comparing them to the natural
infection in primary cells. We have analyzed a few siRNA
experiments carried out in both cell lines as well as in the primary
cells (peripheral blood mononuclear cells: PBMCs [33,34],
peripheral blood lymphocytes: PBLs [10,35] and CD4+ T cells
etc. [36,37]).
Chang et al. reported the efficient inhibition of HIV infection
(.90%) using siRNAs targeting highly conserved pol and vpu
sequences against different strains of HIV-1 in 293T cells and
marked inhibition effect in primary PBMCs [35]. Sang-Kyung Lee
et al. showed that three anti-HIV shRNAs targeting rev, gag, and
vif reduced the p24 level by more than 90%, demonstrating their
ability to protect primary CD4+ T cells, which are the major
targets of HIV-1 infection in vivo, from homologous virus as they
did for HeLa-CD4 cells [37]. Jean-Marc Jacque et al. also
described inhibition of early and late steps of HIV-1 replication in
Magi cells and primary PBLs by six siRNAs targeted to LTR, vif
and nef regions of the HIV-1 genome [10]. These studies suggest
that that siRNA perform equally well in both cell lines and
primary cells.
RNAi has shown great potential of providing a new class of
antiviral therapeutic molecules. Sequence-specific degradation of
viral RNA by siRNAs/shRNA gives promising results for the
treatment of HIV infection. Various studies have shown selective
inhibition of viral genes/proteins that are crucial for HIV-1
replication through transiently expressed synthetic siRNA or
continuous expression of vectors containing shRNAs expression
cassettes. However, there is no single platform having complete
information about siRNA used against HIV. This results in delay
in the literature mining, especially in the presence related articles
describing siRNA targeting the host genes. So as to speedup
research, we have developed HIVsirDB database having compre-
hensive information about the siRNA/shRNA used in the past
targeting every region of the HIV genome.
Users can explore information about the siRNAs/shRNAs
sequences, target HIV genome region, efficacies and the
experimental conditions prior their experiments in user friendly
manner using the search and browsing facility. siRNA analysis
tools will help the users to map siRNA on their target sequences
and to know the siRNA sequence conservation among 1496
reference strains. Simultaneously, HivsirMut will provide effect of
escape mutations and nucleotide mismatch between siRNA and
target on the potency. This information would help in picking up
the best and effective siRNAs and target genome region for further
research.
HIVsirDB, the freely available open source database, would be
very useful to experimentalists in deciding the highly potent
siRNAs targeting the most susceptible target site in HIV genome
and its experimental procedure to suppress HIV infection. The
online submission facility will be helpful for updating this database.
Limitations and future prospects
Our major limitation in developing the database is that the
information about siRNAs/shRNAs targeting HIV are too
scattered. Extensive literature search is required to further expand
the database as numbers of articles were on siRNA/shRNA
targeting the host organism.
In future, HIVsirBD would be expanded by including the
comprehensive information about siRNAs targeting host genes
and their effect on viral entry and propagation. Data of the
multiple siRNA targeting different genome regions simultaneously
would also be integrated. This database will be updated manually
as soon as enough data will be available.
Availability and requirements
HIVsirDB is available at http://crdd.osdd.net/raghava/hivsir/.
To access HIVsirDB World Wide Web is a prerequisite.
Supporting Information
Table S1 Number of Escape Mutations/mismatches at
different positions in the target sequences.
(XLS)
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